797 related articles for article (PubMed ID: 9238754)
1. Histamine in cancer immunotherapy.
Hellstrand K; Hermodsson S; Brune M; Naredi P; Carneskog J; Mellqvist UH
Scand J Clin Lab Invest; 1997 May; 57(3):193-202. PubMed ID: 9238754
[TBL] [Abstract][Full Text] [Related]
2. Histamine and cytokine therapy.
Hellstrand K; Hermodsson S; Naredi P; Mellqvist UH; Brune M
Acta Oncol; 1998; 37(4):347-53. PubMed ID: 9743456
[TBL] [Abstract][Full Text] [Related]
3. Histamine and interleukin-2 in acute myelogenous leukemia.
Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
[TBL] [Abstract][Full Text] [Related]
4. Histamine: a novel approach to cancer immunotherapy.
Hellstrand K; Brune M; Naredi P; Mellqvist UH; Hansson M; Gehlsen KR; Hermodsson S
Cancer Invest; 2000; 18(4):347-55. PubMed ID: 10808371
[TBL] [Abstract][Full Text] [Related]
5. Immune response in blood and tumour tissue in patients with metastatic malignant melanoma treated with IL-2, IFN alpha and histamine dihydrochloride.
Jørkov AS; Donskov F; Steiniche T; Ternesten-Bratel A; Naredi P; Hellstrand K; Hokland M
Anticancer Res; 2003; 23(1B):537-42. PubMed ID: 12680142
[TBL] [Abstract][Full Text] [Related]
6. Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia.
Brune M; Hellstrand K
Br J Haematol; 1996 Mar; 92(3):620-6. PubMed ID: 8616026
[TBL] [Abstract][Full Text] [Related]
7. NK cell-mediated killing of AML blasts: role of histamine, monocytes and reactive oxygen metabolites.
Brune M; Hansson M; Mellqvist UH; Hermodsson S; Hellstrand K
Eur J Haematol; 1996 Oct; 57(4):312-9. PubMed ID: 8982295
[TBL] [Abstract][Full Text] [Related]
8. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
[TBL] [Abstract][Full Text] [Related]
9. Histamine in cancer immunotherapy: a preclinical background.
Hellstrand K
Semin Oncol; 2002 Jun; 29(3 Suppl 7):35-40. PubMed ID: 12068387
[TBL] [Abstract][Full Text] [Related]
10. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment.
Agarwala SS; Sabbagh MH
Expert Opin Biol Ther; 2001 Sep; 1(5):869-79. PubMed ID: 11728221
[TBL] [Abstract][Full Text] [Related]
11. Spotlight on histamine dihydrochloride in acute myeloid leukaemia.
Yang LP; Perry CM
Drugs Aging; 2011 Apr; 28(4):325-9. PubMed ID: 21428467
[TBL] [Abstract][Full Text] [Related]
12. Histamine in immunotherapy of advanced melanoma: a pilot study.
Hellstrand K; Naredi P; Lindner P; Lundholm K; Rudenstam CM; Hermodsson S; Asztély M; Hafström L
Cancer Immunol Immunother; 1994 Dec; 39(6):416-9. PubMed ID: 8001030
[TBL] [Abstract][Full Text] [Related]
13. Tumour cell vaccines that secrete interleukin-2 (IL-2) and interferon gamma (IFN gamma) are recognised by T cells while resisting destruction by natural killer (NK) cells.
Zier KS; Gansbacher B
Eur J Cancer; 1996 Jul; 32A(8):1408-12. PubMed ID: 8869107
[TBL] [Abstract][Full Text] [Related]
14. Histamine dihydrochloride: in the management of acute myeloid leukaemia.
Yang LP; Perry CM
Drugs; 2011 Jan; 71(1):109-22. PubMed ID: 21175244
[TBL] [Abstract][Full Text] [Related]
15. Combined treatment with histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma.
Lindnér P; Rizell M; Mattsson J; Hellstrand K; Naredi P
Anticancer Res; 2004; 24(3b):1837-42. PubMed ID: 15274364
[TBL] [Abstract][Full Text] [Related]
16. Histamine as an adjunct to immunotherapy.
Naredi P
Semin Oncol; 2002 Jun; 29(3 Suppl 7):31-4. PubMed ID: 12068386
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
18. Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Asemissen AM; Scheibenbogen C; Letsch A; Hellstrand K; Thorén F; Gehlsen K; Schmittel A; Thiel E; Keilholz U
Clin Cancer Res; 2005 Jan; 11(1):290-7. PubMed ID: 15671558
[TBL] [Abstract][Full Text] [Related]
19. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
[TBL] [Abstract][Full Text] [Related]
20. Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice.
Asea A; Hermodsson S; Hellstrand K
Scand J Immunol; 1996 Jan; 43(1):9-15. PubMed ID: 8560202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]